Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100

Gothenburg, October 24, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary commercially available technology platform iTANK, announced today that the last patient has been enrolled in the clinical phase I/II study evaluating the company's oncolytic drug candidate ELC-100 (AdVince) against neuroendocrine tumors. The study's preliminary results are expected to be reported in the first half of 2025.

The study, which is sponsored by Uppsala University, is carried out in two stages – a dose escalation study and a dose expansion study. The ongoing, first, dose escalation study primarily aims to evaluate the safety of the treatment in patients and identify the maximum tolerated dose (MTD). During the study, four dose levels are evaluated in three patients each. In addition to the primary goal of the dose escalation study, efficacy is also evaluated, for example the form of tumor response.

The twelfth and last patient of the study has now been enrolled and initiated treatment. The preliminary study results are expected to be presented during the first half of 2025. Based on the outcome of the dose escalation study and subsequent outcome of discussions with regulatory authorities, the company will formulate a strategy for the continued clinical development of ELC-100.

"We have now enrolled the last patient in the dose-escalation stage of our phase I/II clinical trial with ELC-100 in patients affected by neuroendocrine tumors. The unique treatment is based on a virus that has a natural ability to infect and kill cancer cells. We look forward to presenting the results of the first phase of the study and evaluating the next step in our clinical development of ELC-100,” said Jamal El-Mosleh, CEO of Elicera Therapeutics.